Scope and Claims Analysis of US Patent 8,425,462 (Apparatus and Methods for Gas-Driven Medicament Delivery with Post-Delivery Force Release)

US 8,425,462 claims a gas/force-driven, mechanically sequenced medicament delivery apparatus (and related method) in which: (i) a carrier moves to deploy a delivery element (needle) outside a housing, (ii) an energy storage member produces force via pressurized gas to drive an internal moveable member for medicament expulsion, and (iii) a release mechanism with a valve is actuated by a protrusion on the medicament carrier only after delivery, to vent/release pressurized gas and relieve driving force, allowing retraction.

The estate’s claim language is concentrated on event sequencing, valve actuation by carrier features, and force transfer/release timing. The strongest differentiation is the combination of (a) pressurized-gas energy storage plus (b) valve release mechanism actuated after expulsion via a protrusion engagement in a specific moveable-member position.

What does US 8,425,462 claim coverage include for gas-driven medicament delivery devices?

Core coverage (independent claim family theme): the apparatus combines a housing, a moveable medicament carrier, a delivery member (often a needle), and an energy storage member that produces force via pressurized gas. It further includes a moveable member that moves through defined positions to cause expulsion, and a release mechanism that couples to that moveable member and uses a valve engaged by a protrusion to release the pressurized gas after expulsion.

Claim 1: apparatus with valve release actuated in a “third moveable member position”

Claim 1 recites a structured sequence:

Housing
Medicinal carrier movable between:
- First carrier position: delivery member disposed within the housing
- Second carrier position: delivery member partially extending from the housing
Energy storage member: produces force via pressurized gas to move the carrier from first to second position
Delivery member inside housing at first position, protruding at second position
Moveable member with three positional states:
- Moves from first moveable member position to second moveable member position when carrier moves from first to second
- Moves from second moveable member position to third moveable member position while carrier is in the second carrier position
- Discharges medicament through the delivery member when moving from second to third position
Release mechanism coupled to the moveable member:
- Includes a valve configured to engage a protrusion on the proximal portion of the medicament carrier
- Valve releases pressurized gas when the moveable member is in the third position
- Release allows the medicament carrier to move back toward the first carrier position (retraction)

Practical claim-scope implication: to infringe claim 1, an accused device needs (at minimum) the same functional architecture:

deploy delivery element by carrier movement,
expel medicament via internal moveable-member motion,
only after expulsion (timing tied to the moveable-member “third position”), vent/relieve gas force via a valve that is actuated by a protrusion on the carrier.

Claim 9: apparatus variant with piston transferring force and carrier protrusion actuating release

Claim 9 also covers an apparatus, but shifts some architecture:

Housing contains a medicament container coupled to delivery member.
Energy storage member produces force.
Carrier is movable between positions that change delivery-member exposure.
A piston transfers force to the carrier and medicament to move carrier and deliver medicament.
Release mechanism releases force from piston when actuated.
Carrier includes a protrusion that actuates the release mechanism after the portion of the medicament has been delivered.

Practical scope implication: claim 9 is a broader “gas/force + piston + post-delivery release actuated by carrier protrusion” frame, though it may not require the exact three-position moveable-member geometry of claim 1. It does require a piston transferring force and a protrusion that actuates release mechanism after delivery.

Claim 15: method tying motion states to valve opening and gas release

Claim 15 recites a method with event sequencing:

Move carrier from first to second position inside a housing, with a needle inside at first position and partially outside at second.
Move a moveable member from first to second moveable position in response to force produced by energy storage member via pressurized gas to expel medicament via needle.
After expulsion, contact protrusion of carrier with portion of release mechanism to open a valve to release pressurized gas.
Release mechanism configured to release force from moveable member when actuated.

Practical scope implication: a method claim is constrained to the timing (contact and valve opening after expulsion) and to pressurized gas release triggered by carrier protrusion interaction.

How narrow or broad are the claims: what elements are mandatory vs optional?

Mandatory elements for claim 1

Claim 1 is structurally tight. The following are not optional under normal claim interpretation:

Energy storage member configured to produce force via pressurized gas
Medicinal carrier moving from first to second carrier positions (delivery member inside vs outside housing)
Moveable member with three-position sequencing tied to expulsion timing
Discharge occurs when moveable member moves from second to third position
Release mechanism coupled to moveable member
Valve configured to engage a protrusion on proximal portion of medicament carrier
Valve releases pressurized gas when moveable member is in third moveable position
Release permits carrier movement toward first position

Claim 2-4, 7-8: narrowing add-ons

Examples of further limitations:

Claim 2: moveable member substantially stationary relative to medicament carrier when carrier moves first to second.
Claim 3: energy storage member operably coupled to moveable member so force exerts on moveable member to move it from first to second moveable position.
Claim 4: medicament container includes seal fluidically isolating medicament and ruptured when moveable member moves second toward third.
Claim 5: seal + epinephrine.
Claim 6: delivery member is a needle.
Claim 7: biasing member urges medicament carrier toward first position.
Claim 8: retraction spring urges medicament carrier; spring axis offset from longitudinal axis of delivery member.

Claim 9-14: additional structural features

Claim 10: biasing member urges carrier from second to first.
Claim 11: retraction member produces second force after release mechanism actuated.
Claim 12: medicament container seal ruptured when force transferred via piston.
Claim 13: medicament includes epinephrine.
Claim 14: energy storage member produces pressurized gas; valve coupled to proximal end portion of piston; carrier protrusion engages valve after medicament delivered.

These are all typical “design around pressure points” for a competitor: epinephrine is optional unless the claim being asserted specifies it; seal rupture logic and retraction force geometry can narrow the claims but also provide fallback coverage.

Claim 15-17: method limitations that can be harder to design around

Method claims constrain the sequence of operations:

needle deployment timing relative to carrier positions,
force-induced moveable-member motion to expel,
post-expulsion protrusion contact to open valve and release pressurized gas.

Method claim scope tends to be difficult to evade without changing the fundamental actuation sequence.

What patentable subject matter is being claimed: device mechanics, timing logic, and valve actuation?

US 8,425,462 is not claiming a generic injector “in general.” It is claiming a specific mechanical and sequencing architecture:

Energy via pressurized gas to move a carrier and/or drive a piston.
Internal moveable member that transitions through defined positions.
Expulsion event tied to a particular moveable-member transition (e.g., second to third position).
Gas force termination performed by valve release actuated by carrier protrusion engagement.
Post-release retraction enabled by springs/biasing.

This architecture maps to common wearable/auto-injector mechanical sequencing: delivery exposure first, then medicament expulsion, then controlled venting and retraction.

How do the dependent claims impact infringement risk and claim construction?

Valve engagement by a carrier protrusion is the key claim anchor

Across claim 1 and claim 9/14 and method claim 15, the “protrusion actuates valve/release mechanism” feature is the central mechanical link that defines infringement.

Design-around strategies that can avoid literal infringement would typically target one of:

removing a valve that is opened by engagement with a protrusion,
changing the actuation trigger from carrier protrusion to a different actuator,
venting force via a different mechanism not coupled to the asserted moveable-member position,
altering timing such that gas release occurs before expulsion (or via continuous venting) rather than after expulsion.

Three-position moveable member (claim 1) is a structural gate

Claim 1’s moveable member transitions from first to second and then second to third positions, with discharge occurring during the second-to-third transition. Devices that use a different internal motion scheme may fall outside claim 1 while still potentially implicating claim 9 or method claim 15, depending on whether they have post-delivery protrusion-triggered release of piston/gas force.

Seal rupture logic provides additional barriers

Claims 4 and 12 require a medicament container seal fluidically isolating the container and ruptured based on moveable-member motion or piston force transfer. If a competing design uses a different fluidic actuation mechanism (e.g., a different pierce architecture or pre-open path), it may avoid those dependent limitations while still risking independent-claim coverage if core structure is otherwise met.

What therapeutic and product-context limitations are present (epinephrine, needle)?

The claims explicitly support:

Epinephrine (dependent claims 5 and 13). These are narrower fallback positions.
Needle delivery member (dependent claim 6). Independent claims are not restricted to needle unless argued as implicit from surrounding structures; for assertion, the safest reading is: needle is an additional narrowing feature present in at least claim 6, with method claim 15 expressly requiring a needle.

So, full-scope device risk is highest for needle-based autoinjectors with gas-driven sequencing and post-expulsion valve venting.

What jurisdictions and regulatory frameworks tie into US 8,425,462 scope?

US patent claims are enforceable in the United States. The operational relevance to regulation is via device classification and drug delivery adjuncts, but the patent itself is not limited by regulatory pathway. The claims are apparatus/mechanical and do not directly recite FDA drug application categories.

Given the explicit epinephrine mention and needle injector form, the likely regulatory arena is:

FDA-regulated drug labeling (epinephrine)
Combination product or drug-device interface depending on implementation
Autoinjector/pen injection device compliance regimes

This matters for freedom-to-operate because regulatory design choices often track claim language (e.g., needle exposure timing, venting after dose).

How does US 8,425,462 compare across claim 1 vs claim 9 coverage?

Feature	Claim 1	Claim 9
Driving energy	Pressurized gas produces force	Force produced by energy storage member (gas not always explicit in claim 9 text but claim 14 adds gas/valve structure)
Delivery element exposure	Delivery member within housing at first carrier position; extends at second	Delivery member within housing at first position; portion outside at second
Main force-transfer member	“Moveable member” with first/second/third positions; discharge during second to third transition	Piston transfers force to move carrier and deliver medicament
Gas force release mechanism	Valve in release mechanism engages protrusion on carrier; releases gas when moveable member in third position	Release mechanism releases force from piston; carrier protrusion actuates release mechanism after medicament delivery
Post-delivery trigger	Defined by moveable-member third position and protrusion-valve engagement	Defined by protrusion actuating release after delivery
Dependent fallback	Seal rupture and retraction geometry; biasing and spring axis offset	Seal rupture via piston-force; retraction member producing second force

Scope conclusion: claim 1 is more narrowly mechanical with explicit three-position internal sequencing. claim 9 is more piston-centric with post-delivery protrusion-actuated release. A product may avoid claim 1 while still matching claim 9’s piston + protrusion-triggered release logic.

What patent landscape questions can be answered from the claim text alone?

Only the claim text was provided. A full patent landscape requires:

the patent’s bibliographic data (filing date, priority, continuations, assignees),
the patent family,
related later/later patents by the same assignee,
citations and prosecution history.

Those are not present here. Under the constraints, no landscape comparisons to other patents can be asserted without the required bibliographic facts.

So the analysis below is limited to scope, claim structure, and infringement-risk levers, not an evidentiary map of other patents.

Key Takeaways

US 8,425,462 is centered on a gas/force-driven medicament delivery apparatus that uses an internal moveable member/piston sequence to expel medicament and then a valve release mechanism actuated by a carrier protrusion after expulsion to vent/release gas force and enable retraction.
The strongest claim anchor is the combination of (i) pressurized gas force plus (ii) valve engagement by a carrier protrusion plus (iii) timing tied to moveable-member position or “after medicament delivered.”
Claim 1 requires the more specific “moveable member through first/second/third positions with discharge during second to third” structure.
Claim 9 provides a piston-centric path with protrusion-triggered post-delivery release.
Method claim 15 mirrors the mechanical sequence into operational steps, making timing and actuation interactions critical for any activity-based infringement analysis.

FAQs

Does US 8,425,462 cover devices where gas is vented continuously during expulsion rather than after expulsion?
Is epinephrine required to infringe US 8,425,462?
How does a non-piston force transfer design affect risk under claim 9?
Can a design that triggers valve actuation by a separate switch instead of carrier protrusion avoid infringement?
If a device uses a different internal motion scheme but still retracts after medicament expulsion, does it still fall within claim 1’s three-position moveable member concept?

References

No references are provided because no bibliographic identifiers, family data, or external source text were supplied beyond the claim set in the prompt.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004325202	⤷ Start Trial
Australia	2006210865	⤷ Start Trial
Australia	2007245139	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,425,462

Summary for Patent: 8,425,462